Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥2 HER2-Directed Regimens: Phase III NALA TrialJ. Clin. Oncol 2020 Jul 17;[EPub Ahead of Print], C Saura, M Oliveira, YH Feng, MS Dai, SW Chen, SA Hurvitz, SB Kim, B Moy, S Delaloge, W Gradishar, N Masuda, M Palacova, ME Trudeau, J Mattson, YS Yap, MF Hou, M De Laurentiis, YM Yeh, HT Chang, T Yau, H Wildiers, B Haley, D Fagnani, YS Lu, J Crown, J Lin, M Takahashi, T Takano, M Yamaguchi, T Fujii, B Yao, J Bebchuk, K Keyvanjah, R Bryce, A Brufsky
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.